Does Low-grade Follicular Lymphoma With a High Proliferation Index Require a Different Treatment Strategy? A Single Center Experience.

IF 1.6 4区医学 Q4 ONCOLOGY

Anticancer research Pub Date : 2025-01-01 DOI:10.21873/anticanres.17408

Rahim A Jiwani, Eiraj Khan, Hassan Abdulahi, Urwat Vusqa, Cyrus Khan, Yazan Samhouri

{"title":"Does Low-grade Follicular Lymphoma With a High Proliferation Index Require a Different Treatment Strategy? A Single Center Experience.","authors":"Rahim A Jiwani, Eiraj Khan, Hassan Abdulahi, Urwat Vusqa, Cyrus Khan, Yazan Samhouri","doi":"10.21873/anticanres.17408","DOIUrl":null,"url":null,"abstract":"Background/aim: Follicular lymphoma (FL) is the most common indolent non-Hodgkin lymphoma worldwide. Patients can have a wide range of clinical features and behavior which does not necessarily correlate to histologic grade or Ki-67 proliferation index. We hypothesized that patients with low grade but high proliferative index (LG/HP) FL have a more aggressive disease course. The aim of this study was to determine the role of LG/HP on the outcomes of FL patients.Patients and methods: A retrospective single center study of FL patients treated within the Allegheny Health Network was conducted from January 2011 to December 2021. Patients were divided into three groups: low grade/high proliferation index (PI) (LG/HP), low grade/low PI (LG/LP), and high grade (HG). Cox regression models looking at variables including age, sex, race, Ann Arbor staging, PET SUVmax, FLIPI score, and treatment details were used to analyze predictors of progression. Survival estimates were calculated using the Kaplan-Meier method and compared using the Log-rank test.Results: A total of 145 patients were treated for FL during the study period. Most were males and fell into the LG/LP group. We determined that the median progression-free survival in the LG/HP group was numerically worse than the LG/LP group; however, this did not meet statistical significance.Conclusion: Our data suggest that a different treatment approach may not be warranted for LG/HP FL patients.","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 1","pages":"225-228"},"PeriodicalIF":1.6000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anticancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/anticanres.17408","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background/aim: Follicular lymphoma (FL) is the most common indolent non-Hodgkin lymphoma worldwide. Patients can have a wide range of clinical features and behavior which does not necessarily correlate to histologic grade or Ki-67 proliferation index. We hypothesized that patients with low grade but high proliferative index (LG/HP) FL have a more aggressive disease course. The aim of this study was to determine the role of LG/HP on the outcomes of FL patients.

Patients and methods: A retrospective single center study of FL patients treated within the Allegheny Health Network was conducted from January 2011 to December 2021. Patients were divided into three groups: low grade/high proliferation index (PI) (LG/HP), low grade/low PI (LG/LP), and high grade (HG). Cox regression models looking at variables including age, sex, race, Ann Arbor staging, PET SUV_max, FLIPI score, and treatment details were used to analyze predictors of progression. Survival estimates were calculated using the Kaplan-Meier method and compared using the Log-rank test.

Results: A total of 145 patients were treated for FL during the study period. Most were males and fell into the LG/LP group. We determined that the median progression-free survival in the LG/HP group was numerically worse than the LG/LP group; however, this did not meet statistical significance.

Conclusion: Our data suggest that a different treatment approach may not be warranted for LG/HP FL patients.

查看原文本刊更多论文

高增殖指数的低级别滤泡性淋巴瘤需要不同的治疗策略吗？单一中心体验。

背景/目的：滤泡性淋巴瘤（滤泡性淋巴瘤）是世界上最常见的惰性非霍奇金淋巴瘤。患者可能具有广泛的临床特征和行为，这些特征和行为不一定与组织学分级或Ki-67增殖指数相关。我们假设低级别但高增殖指数（LG/HP）的FL患者病程更具侵袭性。本研究的目的是确定LG/HP对FL患者预后的作用。患者和方法：2011年1月至2021年12月，在阿勒格尼健康网络内对FL患者进行了回顾性单中心研究。患者分为低分级/高增殖指数组（LG/HP）、低分级/低PI组（LG/LP）和高分级组（HG）。Cox回归模型考虑了年龄、性别、种族、安娜堡分期、PET SUVmax、FLIPI评分和治疗细节等变量，用于分析进展的预测因素。使用Kaplan-Meier法计算生存估计，并使用Log-rank检验进行比较。结果：在研究期间，共有145例患者接受了FL治疗。大多数是男性，属于LG/LP组。我们确定LG/HP组的中位无进展生存期在数字上比LG/LP组差；然而，这并没有达到统计学意义。结论：我们的数据表明，LG/HP FL患者可能不需要采用不同的治疗方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Anticancer research 医学-肿瘤学

CiteScore

3.70

自引率

10.00%

发文量

566

审稿时长

2 months

期刊介绍： ANTICANCER RESEARCH is an independent international peer-reviewed journal devoted to the rapid publication of high quality original articles and reviews on all aspects of experimental and clinical oncology. Prompt evaluation of all submitted articles in confidence and rapid publication within 1-2 months of acceptance are guaranteed. ANTICANCER RESEARCH was established in 1981 and is published monthly (bimonthly until the end of 2008). Each annual volume contains twelve issues and index. Each issue may be divided into three parts (A: Reviews, B: Experimental studies, and C: Clinical and Epidemiological studies). Special issues, presenting the proceedings of meetings or groups of papers on topics of significant progress, will also be included in each volume. There is no limitation to the number of pages per issue.